Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.33 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4480923 | 0.79 | P2RX7 (0.38) | CYP11B2AGTR1PPARGP2RX7KDM4E | |
| SCHEMBL4486440 | 0.77 | AGTR1 (0.34) | AGTR1PPARGKDM4ECMA1MAOB | |
| SCHEMBL4469849 | 0.76 | P2RX7 (0.33) | CYP11B2KCNA3P2RX7KDM4EALDH1A1 | |
| SCHEMBL4492080 | 0.73 | CYP11B2 (0.36) | CYP11B2P2RX7KDM4EALDH1A1GAA | |
| SCHEMBL4484398 | 0.73 | CYP11B2 (0.36) | CYP11B2P2RX7KDM4EALDH1A1GAA | |
| SCHEMBL4485481 | 0.73 | CYP11B2 (0.36) | CYP11B2P2RX7KDM4EALDH1A1GAA | |
| SCHEMBL4478622 | 0.73 | ALDH1A1 (0.41) | CYP11B2KCNA3P2RX7KDM4EALDH1A1 | |
| SCHEMBL4470424 | 0.73 | CMA1 (0.35) | AGTR1PPARGCMA1 | |
| SCHEMBL4470416 | 0.73 | CMA1 (0.35) | AGTR1PPARGCMA1 | |
| SCHEMBL4486655 | 0.69 | CCR2 (0.33) | AGTR1PPARGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | CYP11B2 797/4885KCNA3 84/4885AGTR1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.